Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Capital Expenditures for 2 consecutive years, with $13399.0 as the latest value for Q1 2025.

Quarterly Capital Expenditures changed N/A to $13399.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $13399.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $13399.0 for FY2025, N/A changed from the prior year.
Capital Expenditures for Q1 2025 was $13399.0 at Inhibikase Therapeutics, down from $200166.0 in the prior quarter.
The five-year high for Capital Expenditures was $200166.0 in Q3 2022, with the low at $13399.0 in Q1 2025.